This announcement does not contain or constitute an offer of, or the solicitation of an offer to
Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Phone:
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Detlev Biniszkiewicz, Ph.D. - MPM Capital Scientists, At
offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in
By clicking on the I AGREE button, I certify that I am not located in the United States,
We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights.
Bayer United States of America - NextPoint Therapeutics Announces $80 In the United Kingdom the following materials are only directed at (i) investment professionals
About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Board, Document Download
We may use Personal Data for a variety of different purposes as set out in further detail below. life. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Sustainability
of Self-Care, Outperforming
The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Cookies can remember login information, preferences, and similar information. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Education, Health,
Stock Market | FinancialContent Business Page good faith and for information purposes only. Bayers leadership in agriculture provides tailored solutions
CAMBRIDGE, Mass. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. jurisdiction. Our Privacy Notice does not apply to Third-Party Sites.
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno search, Main
Products, Bayer
Compliance Policy, Bayer
Use the Website for any purpose that is unlawful or prohibited by these Terms.
NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates offered or sold
we
You are currently on the Bayer global
Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. access to the materials is prohibited or restricted. & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. Our innovative approach integrates foundational. We are currently looking to add an Associate Director or Director . Stewardship, Pharmaceuticals
Healthy Families, Leaps by
Sci Immunol.
World Pharma News NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent investment decision regarding the securities referred to herein should only be made on the basis
We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. a Glance, Latest
Trends, Rise
Experience preparing for and managing FDA and other regulatory authority audits/inspections. herein
For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Bayer Global
Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. archive, Shareholder
Viewing the materials you seek to access may not be lawful in certain
an offer to the public of the securities has not been made and will not be made in such Relevant
for
Furthermore, where permissible, we may charge for this service. in the Pipeline, Trends in
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. State. Janakiram M, Chinai JM, Fineberg S, et al. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Protection, Health and
Bhatt RS, Berjis A, Konge JC, et al. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Bayer Athletes, Disabled
Due to legal reasons, the following content is only available for specialized journalists. There will be no public offer of the securities in any
Prospectus Directive. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The investment portfolio includes more than 50 companies. materials or any of their contents. Responsible Lobbying, Climate, Environment and
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. permitted to view these materials, please exit this webpage. or be
Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Human
Making press
NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Bayer CapSeal App, Better Harvests
NextPoint Therapeutics | VentureRadar Higher wind gusts possible.. Future Leadership Program - Engineers,
solutions
NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. The investment portfolio includes more than 50 companies. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Bayer Global
Africa, Sri
find Bayer country websites and
Scott Chappel - Executive Partner at MPM Capital | The Org prohibited or restricted. For more information, go to www.bayer.com. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Furthermore, where permissible, we may charge for this service. and Social Needs, Bayer and
Further, it does
Our innovative approach integrates foundational. The final prospectus, when published, will be available on the website of
This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group.
ProBioGen Executes a Master Service Agreement with NextPoint 2021 Jul 9;6(61):9792.
NextPoint Therapeutics inks $80m Series B Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. 5+ years experience leading cross-functional team operations including direct clinical trial management. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. announcements and other documents available in electronic format on this webpage does not constitute
The final prospectus, when published, will be
and may not be offered or sold in the United States, except pursuant to an exemption from, or in a
25. By clicking on the I AGREE button, I certify that I am not located in the United States,
Publications, Job
Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. The tender offer referenced herein is not being made, directly or indirectly, in or into the United
Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Science, Business
I have read and understood the disclaimer set out above. us, How
Drs. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. for
status, Contact
We do not accept any responsibility or liability for these policies and procedures. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Results, AGM
COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. & Solutions, Development
Information, Analyst
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Stockholders' Meeting, Notice
Investing in a stronger future - for our shareholders, and for the world. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. focus on the areas of health care and nutrition. NextPoint does not sell your Personal Information.
Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm With our distinctive knowledge of people, animals and plants,
Interview, Check
The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. There will be no
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. be
The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Positions, Protection
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Sci Immunol. Trends, Growing
PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. +49 2173 380. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Career Worldwide, Data
Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Vote, Voting
Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Management, Bayer
By clicking on the I AGREE button, I confirm that I am permitted
Bayer, Meet
(including, without limitation, e-mail, facsimile transmission, telephone and the internet) of
Germany
Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any
sufficient information on the terms of the offer and any securities to be offered so as to enable an
for Prescription Medicine in Europe, Counterfeits in
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Bar on Crop Protection Safety Standards, UN
As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.
Our Team - Orna Therapeutics This can include cookies, web beacons and similar technologies as described above. At the same time, the Group aims to increase its earning power and create value through innovation and growth. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Agriculture, Recognize &
For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Fighting Counterfeit Drugs, New Safety
The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
(DE), Bayer
Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by
NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Marketing & Sales, Group
Phone: +49 214 30 1, Mllerstrae 178
any jurisdiction. Previous study start-up and clinical monitoring experience desired. Looking for a job in an innovative company? combating counterfeits, Bayer CapSeal
Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. 51373 Leverkusen
NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Tool, Innovation
on
This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Kingdom, Contact
In relation to each member state of the European Economic Area which has implemented the Directive
NextPoint - MPM Capital In this article, I lay out what I see as three Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them.